Telix Pharmaceuticals (TLX) Notes Payables (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Notes Payables for 3 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • Quarterly Notes Payables rose 5.57% to $13.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, up 5.57% year-over-year, with the annual reading at $13.1 million for FY2025, 11.45% up from the prior year.
  • Notes Payables for Q4 2025 was $13.1 million at Telix Pharmaceuticals, up from $12.4 million in the prior quarter.
  • The five-year high for Notes Payables was $13.1 million in Q4 2025, with the low at $627554.8 in Q4 2023.
  • Average Notes Payables over 3 years is $8.7 million, with a median of $12.4 million recorded in 2024.
  • The sharpest move saw Notes Payables skyrocketed 1878.89% in 2024, then rose 5.57% in 2025.
  • Over 3 years, Notes Payables stood at $627554.8 in 2023, then surged by 1878.89% to $12.4 million in 2024, then rose by 5.57% to $13.1 million in 2025.
  • According to Business Quant data, Notes Payables over the past three periods came in at $13.1 million, $12.4 million, and $627554.8 for Q4 2025, Q4 2024, and Q4 2023 respectively.